Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with "no serious adverse events", according to research published in The Lancet Friday, but experts said the trials were too small to prove safety and effectiveness.

COVID-19: Russia vaccine 'passes early trial test'

the-lancet-friday

The Lancet Friday, News on The Lancet Friday, stories on The Lancet Friday, articles on The Lancet Friday, The Lancet Friday stories at Wion, The Lancet Friday news, The Lancet Friday latest news

the lancet-friday

COVID-19: Russia vaccine 'passes early trial test'